| Detected | Trial | Change |
|---|---|---|
| 2026-06-05 | NCT06780930 Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or… |
date change Primary completion pushed: 2025-10-02 -> 2026-05-07 |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-05 | NCT07629089 VorAsidenib With Lomustine In Patients With rEcurrent IDH-mutaNT Glioma Harboring IDH1… | Phase 1 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06809322 | Vorasidenib Maintenance for IDH Mutant Astrocytoma | IDH-mutant Grade 2 or 3 Astrocytoma | Recruiting |
| NCT06780930 | Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or… | Residual or Recurrent Grade 2 IDH Mutant Glioma | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT06478212 | Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma | IDH1-mutant Glioma | Active, Not Recruiting |
| Phase 1 | |||
| NCT07250633 | Pharmacokinetic Study of Vorasidenib in Severe Hepatically Impaired and Matched-Control… | Severe Hepatic Impairment | Recruiting |
| NCT05484622 | Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1… | Astrocytoma | Active, Not Recruiting |
| NCT07629089 | VorAsidenib With Lomustine In Patients With rEcurrent IDH-mutaNT Glioma Harboring IDH1… | Brain Cancer | Not Yet Recruiting |
| Not specified | |||
| NCT07240662 | Vorasidenib in CNS WHO Grade 2 IDH-mutant Diffuse Glioma | Glioma | Recruiting |
| NCT07547163 | Patient Voice in the Treatment of Low-grade Gliomas: Use of Patient-reported Outcomes… | Glioma | Recruiting |